Table 3.
Correlation between IGF2BP3 expression and the patient demographics and endoscopic findings in HGIN
| Characteristics | IGF2BP3 expression
|
P-value | |
|---|---|---|---|
| Positive (n=68) | Negative (n=44) | ||
| Gender | 0.282 | ||
| Male | 44 | 24 | |
| Female | 24 | 20 | |
| Age (years) | 0.754 | ||
| ≤50 | 14 | 8 | |
| >50 | 54 | 36 | |
| Location | 0.294 | ||
| Upper | 16 | 16 | |
| Middle | 19 | 12 | |
| Lower | 33 | 16 | |
| Length | 0.731 | ||
| ≤5 cm | 49 | 33 | |
| >5 cm | 19 | 11 | |
| Circumferential extent | 0.370 | ||
| <1/2 | 15 | 15 | |
| 1/2–2/3 | 30 | 16 | |
| >2/3 | 23 | 13 | |
| pT stage | 0.042 | ||
| pT1a-EP | 8 | 13 | |
| pT1a-LPM | 23 | 15 | |
| pT1a-MM | 37 | 16 | |
Notes: pT stage: pathological T stage; pT1a-EP: M1, carcinoma in situ; pT1a-LPM: M2, tumor-invaded lamina propria mucosa; pT1a-MM: M3, tumor invaded the whole layer of mucosa.
Abbreviations: HGIN, high-grade intraepithelial neoplasia; IGF2BP3, insulin-like growth factor-II mRNA-binding protein-3.